Corona Virus

FDA approves controversial Alzheimer’s therapy despite mixed evidence

The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.Read More

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top